2026-07422NoticeWallet

FDA Sets Review Period for UNLOXCYT Patent Extension

Published Date: 4/16/2026

Notice

Summary

The FDA has set the official review period for UNLOXCYT, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind UNLOXCYT and anyone interested in patent timing or drug development. If you think the dates are wrong or want to challenge the company’s diligence, you have until mid-2026 to speak up—potentially impacting patent length and market exclusivity.

Analyzed Economic Effects

2 provisions identified: 2 benefits, 0 costs, 0 mixed.

FDA Sets 2,000-Day Review Period

If you are the patent holder or work for the company behind UNLOXCYT, FDA has officially determined the regulatory review period is 2,000 days (1,289 days testing phase and 711 days approval phase). This determination establishes the maximum potential length of a patent extension; the applicant (Checkpoint Therapeutics, Inc.) seeks 196 days of patent term extension.

Deadlines to Challenge Dates or Diligence

If you believe any published dates are wrong, you must submit comments asking for a redetermination by June 15, 2026. If you want FDA to decide whether the applicant acted with due diligence during the review period, you may file a petition by October 13, 2026.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Comments Due
4/16/2026
6/15/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register